CDK4/6 signaling pathway and its targeted therapeutic agents in cancer therapy: a review / 生物工程学报
Chinese Journal of Biotechnology
; (12): 2232-2239, 2021.
Article
in Zh
| WPRIM
| ID: wpr-887792
Responsible library:
WPRO
ABSTRACT
The development and progression of most cancers have been well recognized as the result of highly activated cell cycle. Cyclin dependent kinase 4/6 plays important roles not only in mitosis, but also in multiple biological processes that contribute to cancer development, such as aging, apoptosis and histone modification. Three FDA approved CDK4/6 inhibitors, Palbociclib, Ribociclib and Abemaciclib, have been used as targeted cancer therapeutic agents to benefit patients with endocrine therapy-resistant breast cancer and other types of cancer, prolonging their survival. However, the clinical application of these inhibitors also leads to acquired drug resistance and other problems. This paper reviews the regulatory roles of CDK4/6, the application of CDK4/6 inhibitors in cancer and the challenge of drug resistance.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Breast Neoplasms
/
Signal Transduction
/
Protein Kinase Inhibitors
/
Cyclin-Dependent Kinase 4
/
Cyclin-Dependent Kinase 6
/
Molecular Targeted Therapy
Limits:
Female
/
Humans
Language:
Zh
Journal:
Chinese Journal of Biotechnology
Year:
2021
Type:
Article